Phocas Financial’s Acadia Pharmaceuticals ACAD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-77,245
Closed -$1.95M – 5
2026
Q2
$1.95M Sell
77,245
-4,102
-5% -$90.2K 0.27% 116
2026
Q1
$1.81M Sell
81,347
-22,725
-22% -$543K 0.28% 114
2025
Q4
$2.78M Sell
104,072
-271
-0.3% -$6.48K 0.36% 101
2025
Q3
$2.23M Buy
104,343
+2,167
+2% +$51.2K 0.29% 109
2025
Q2
$2.2M Buy
102,176
+15
+0% +$279 0.32% 100
2025
Q1
$1.7M Sell
102,161
-5,650
-5% -$103K 0.26% 107
2024
Q4
$1.98M Buy
+107,811
New +$1.74M 0.26% 112
2023
Q4
$2.1M Buy
66,957
+1,266
+2% +$30.2K 0.28% 115
2023
Q3
$1.37M Buy
+65,691
New +$1.78M 0.2% 120

Other funds holding ACAD

Phocas Financial's ACAD Position: Q3 2026 in Review

Phocas Financial sold out of Acadia Pharmaceuticals (ACAD) in Q3 2026, closing a stake of 77,245 shares — an estimated $1.95M sold.

Phocas Financial first reported a position in ACAD in Q3 2023 and held it in 9 quarters. The position peaked at $2.78M in Q4 2025. 350 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.

  • Phocas Financial reported no remaining Acadia Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Phocas Financial sold 77,245 Acadia Pharmaceuticals shares in Q3 2026, an estimated $1.95M.
  • Phocas Financial first reported a position in Acadia Pharmaceuticals in Q3 2023 and held it in 9 quarters.
  • Phocas Financial's Acadia Pharmaceuticals position peaked at $2.78M in Q4 2025.
  • 350 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.

Based on Phocas Financial's 13F filing for Q3 2026.